Agrigento V, Barone R, Sclafani S, Di Maggio R, Sacco M, Maggio A, D'Alcamo E
U.O.C. Ematologia per le Malattie Rare del Sangue e degli Organi Ematopoietici, Azienda Ospedali Riuniti Villa Sofia-Cervello, Via Trabucco n. 180, 90146 Palermo, Italy.
Indian J Hematol Blood Transfus. 2017 Dec;33(4):621-623. doi: 10.1007/s12288-016-0765-9. Epub 2016 Dec 18.
Congenital dyserythropoietic anemia type I (CDAI) is an autosomal recessive inherited haematological disorder associated with moderate-to-severe anemia characterized by ineffective erythropoiesis with distinct morphological abnormalities in erythroid precursors. We present two case of congenital dyserythropoietic anemia type I in two Sicilian patients heterozygous for β 39 globin gene cod 39 C > T with marked bone marrow abnormalities, responding to treatment with alpha interferon. The diagnosis was established using routine haematological and biochemical test, light and electron microscopy; molecular analysis of the CDAN1 gene associated to the CDAI disease was performed. The response to the treatment was monitored using the hemoglobin levels, the red cell count, the reticulocyte count and the transfusional requirement. This report points out the usefulness of the treatment with interferon alpha in two Sicilian beta thalassemia carriers, in which the therapy was well tolerated without producing any side effects; in these patients the transfusion requirements after the initiation of interferon therapy decreased.
I型先天性红细胞生成异常性贫血(CDAI)是一种常染色体隐性遗传性血液系统疾病,与中重度贫血相关,其特征为无效红细胞生成,伴有红系前体细胞明显的形态学异常。我们报告了两名西西里岛患者患I型先天性红细胞生成异常性贫血的病例,这两名患者为β39珠蛋白基因第39位密码子C>T杂合子,有明显的骨髓异常,对α干扰素治疗有反应。通过常规血液学和生化检查、光镜和电镜检查确诊;对与CDAI疾病相关的CDAN1基因进行了分子分析。使用血红蛋白水平、红细胞计数、网织红细胞计数和输血需求来监测治疗反应。本报告指出,α干扰素治疗对两名西西里岛β地中海贫血携带者有效,该疗法耐受性良好,未产生任何副作用;在这些患者中,干扰素治疗开始后输血需求减少。